Accepted for publication 13 July 1989 Material and methods
COMMERCIAL TESTS
Toxoplasma gondii IgM ELISA (Clark Laboratories Inc., Jamestown, New York) The principle of this test is based on an indirect solid phase enzyme immunoassay. The procedure is carried out in three basic reaction steps. Ninety six well 12 x 8 strip polystyrene microtitre plates are coated alternatively with toxoplasma antigen and control antigen. After the patient's serum has been incubated horseradish peroxidase conjugated anti-human IgM is added. Peroxidase activity is detected using o-phenylenediamine (OPD) and hydrogen peroxide. The colour intensity is determined in a spectrophotometer at 492 nm. Control well absorbance is substracted from antigen well absorbance for each sample. Potential interference from such factors as rheumatoid factor are averted by treating serum samples with goat anti-human IgG before running the assay. The overall incubation time for this assay is one hour and 10 minutes. A total of81 sera sent to our laboratory to be tested for the presence of toxoplasma antibodies were used for serological comparison. The serum samples were classified in different series. Series A consisted ofseven follow up sera from a single patient with an acute toxoplasma infection. The sera were taken from one week after onset of clinical symptoms, and over a period of two years. Series B consisted of 10 sera from patients with no evidence of a recent toxoplasmosis but with antiviral IgM antibodies detectable in their sera. This group included the serum of two patients with hepatitis A, one with rubella, one with measles, one with mumps, one with herpes simplex, two with cytomegalovirus and two with Epstein Barr virus IgM antibodies. Series C consisted of 10 sera from rheumatoid factor positive patients. Four of these patients also had antinuclear antibodies.
Series D consisted of 28 sera from patients with toxoplasma specific IgM antibodies as defined in the reference ELISA. A recent toxoplasmosis in these patients was further confirmed by a rise in IgG in subsequent samples or the presence of clinical symptoms. Series E consisted of 14 sera from patients with lymphadenopathy but with no detectable IgM antibodies to toxoplasma in the reference ELISA. Series F consisted of 12 sera from pregnant women without clinical symptoms suggesting a recent infection, without detectable IgM antibodies in the reference ELISA, and for whom toxoplasma specific IgG titres remained constant for a period of over at least one month.
There was no significant difference between the age distribution and the amount of toxoplasma specific IgG antibodies for the patients in series B, C, E and F. Table 1 shows the ELISA results of the follow up sera from a recently infected patient (sera of series A). In three ELISAs (Abbott, Pasteur, and Labsystems) IgM antibodies were detected during the entire follow up period of two years. The ELISA of Hybritech, on the other hand, already gave negative results four to seven months after the first sample had been taken. Table 2 summarises the results for the sera of series B to F. None of the sera with antiviral IgM antibodies (series B) gave a positive result in any of the commercial ELISAs. In the reference ELISA one serum, containing hepatitis A virus IgM antibodies, was positive. This serum was clearly negative in immunoblotting.
Results
With exception of the Hybritech ELISA, all tests gave positive results for one or two sera positive for rheumatoid factor (series C). One of these positive patients gave a positive or equivocal result in four of the six commercial ELISAs (Abbott, Clark Laboratories, Labsystems, Pasteur), and in the reference ELISA. This serum was also positive by immunoblotting, suggesting that this patient still had low toxoplasma specific IgM antibody titres due to a recent infection. In the Organon ELISA two other patients positive for rheumatoid factor were reported positive. One of these patients was also positive in the Clark Laboratories ELISA. None of these patients was found to be positive by immunoblotting. All the 28 sera from patients with a recent toxoplasmosis were found to be positive by immunoblotting and in four of the six commercial ELISAs (Abbott, Labsystems, Organon, Pasteur). The ELISAs of Hybritech and Clark Laboratories, on the other hand, only detected antibodies in, respectively, 19 and 25 of these sera.
All the 14 sera from patients with lymphadenopathy but with a negative result in the reference ELISA (sera of series E), were also found to be negative in four of the six commercial ELISAs (Abbott, Hybritech, Labsystems, and Organon). The Pasteur ELISA gave a weakly positive result for one patient. Another patient was clearly found to be positive in the Clark Laboratories ELISA. These patients were found to be negative by immunoblotting.
Only two of the six commercial ELISAs reported as negative all of the 12 sera from pregnant women who had no indications of a recent infection and were found to be negative in the reference ELISA (series F). The overall agreement between four of the six The presence of rheumatoid factor is seen as one of the most important sources of false positive results in the IgM detection systems. Interference of rheumatoid factor in the indirect ELISA without pre-treatment of the sera has been clearly shown.'9 0 The presence of rheumatoid factor interference in the antibody capture ELISA is still a matter of controversy.269 In our study only the Organon ELISA, which is an antibody capture ELISA, showed pronounced rheumatoid factor interference. These findings contrast with the results of Joynson et al, who found rheumatoid factor interference in the Abbott ELISA but not in the test of Organon.2' Interference with antiviral IgM antibodies was not demonstrable in any of the commercial ELISAs.
In conclusion, the IgM ELISAs of Abbott, Labsystems, and Pasteur have a high sensitivity and a high specificity, although in the ELISAs of Labsystems and Pasteur false positive results cannot be ruled out completely. The Organon ELISA can also be seen as a useful test, although it is less sensitive and the user has to be aware of possible rheumatoid factor interference. We found that the Hybritech ELISA is too insensitive and that the Clark Laboratories ELISA is both insensitive and unspecific. 
